Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.49
-2.0%
$5.00
$3.42
$7.20
$257.46M1.751.56 million shs692,364 shs
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$1.24
-3.9%
$1.22
$0.86
$3.78
$282.16M0.313.31 million shs1.87 million shs
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$1.78
-8.2%
$1.88
$1.29
$13.07
$72.89M-0.131.18 million shs1.03 million shs
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$6.25
-2.8%
$5.36
$3.79
$14.60
$322.16M-0.911.50 million shs1.57 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-1.97%-1.54%-23.25%+3.46%-26.27%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-3.88%+3.33%-7.46%-11.43%-58.39%
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-8.25%-4.30%-24.58%+11.95%-66.79%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-2.80%+19.27%+21.83%+37.97%-5.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.2965 of 5 stars
0.01.00.00.02.60.80.6
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
3.6389 of 5 stars
4.51.00.00.03.63.30.6
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
3.505 of 5 stars
3.64.00.00.03.42.50.6
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
2.4737 of 5 stars
3.61.00.00.03.41.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
2.90
Moderate Buy$8.44581.00% Upside
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
3.18
Buy$21.401,102.25% Upside
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
3.20
Buy$22.00252.00% Upside

Current Analyst Ratings Breakdown

Latest BMEA, ALLO, CADL, and ACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/30/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$23.00
6/24/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/13/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/3/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$7.00
6/2/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/15/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $4.00
5/15/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.02$0.60 per share7.49$7.78 per share0.58
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$20K13,561.26N/AN/A$2.01 per share0.62
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/A$1.42 per shareN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$120K2,609.38N/AN/A$1.41 per share4.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1140.8210.20N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$257.59M-$1.23N/AN/AN/AN/A-52.98%-41.28%8/6/2025 (Estimated)
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$138.43M-$3.55N/AN/AN/AN/A-197.71%-134.84%7/30/2025 (Estimated)
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)

Latest BMEA, ALLO, CADL, and ACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.17N/AN/AN/AN/AN/A
8/6/2025Q1 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.18N/AN/AN/A$96.83 millionN/A
8/6/2025N/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.28N/AN/AN/AN/AN/A
7/30/2025Q2 2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$0.64N/AN/AN/AN/AN/A
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/13/2025Q1 2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.28-$0.28N/A-$0.28$0.00 millionN/A
5/13/2025Q1 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.24$0.13+$0.37$0.13N/AN/A
5/5/2025Q1 2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$0.84-$0.80+$0.04-$0.80N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/AN/AN/AN/AN/A
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/AN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/A
9.71
9.71
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/A
2.25
2.25
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
0.01
4.64
4.64

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
83.63%
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
96.72%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
13.93%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
13.20%
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
18.42%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
16.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.21 million56.21 millionOptionable
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
310218.73 million189.86 millionOptionable
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
5037.57 million30.65 millionOptionable
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
6050.10 million41.79 millionOptionable

Recent News About These Companies

Brookline Capital Management Predicts CADL Q2 Earnings
Research Analysts Offer Predictions for CADL Q2 Earnings
CADL - Candel Therapeutics Inc Ownership - Morningstar
Candel Sinks on New CFO

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.49 -0.09 (-1.97%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$4.49 0.00 (0.00%)
As of 07/15/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Allogene Therapeutics stock logo

Allogene Therapeutics NASDAQ:ALLO

$1.24 -0.05 (-3.88%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$1.26 +0.02 (+1.61%)
As of 07/15/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Biomea Fusion stock logo

Biomea Fusion NASDAQ:BMEA

$1.78 -0.16 (-8.25%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$1.84 +0.05 (+3.09%)
As of 07/15/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Candel Therapeutics stock logo

Candel Therapeutics NASDAQ:CADL

$6.25 -0.18 (-2.80%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$6.36 +0.11 (+1.68%)
As of 07/15/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.